Delay of simian human immunodeficiency virus infection and control of viral replication in vaccinated macaques challenged in the presence of a topical microbicide

AIDS

Volumn 25, Issue 15, 2011, Pages 1833-1841

  Cheng Mayer, Cecilia ^a   Huang, Yaoxing ^a   Gettie, Agegnehu ^a   Tsai, Lily ^a   Ren, Wuze ^a   Shakirzyanova, Madina ^a   Sina, Silvana T ^a   Trunova, Nataliya ^a   Blanchard, James ^b   Jenkins, Lisa M Miller ^c   Lo, Yungtai ^d   Schito, Marco L ^e   Appella, Ettore ^c  

^a AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

HIV; nucleocapsid inhibitor; prevention; topical microbicide; vaccine

Indexed keywords

DNA; DNA VACCINE; GLYCOPROTEIN GP 120; MICROBICIDE; NUCLEOCAPSID PROTEIN;

ARTICLE; CONTROLLED STUDY; DNA IMMUNIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HETEROSEXUALITY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; MACACA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSGENE; VIREMIA; VIRUS REPLICATION;

ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV-1; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 80052948657     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834a1d94     Document Type: Article

References (40)

1. UNAIDS. 2008 Report on the Global AIDS Epidemic. In: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2008.
2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
4. Merson M, Padian N, Coates TJ, Gupta GR, Bertozzi SM, Piot P, et al. Combination HIV prevention. Lancet 2008; 372:1805-1806.
5. Piot P, Bartos M, Larson H, Zewdie D, Mane P. Coming to terms with complexity: a call to action for HIV prevention. Lancet 2008; 372:845-859.
6. Excler JL, Rida W, Priddy F, Gilmour J, McDermott AB, Kamali A, et al. AIDS vaccines and preexposure prophylaxis: is synergy possible? AIDS Res Hum Retroviruses 2011; 27:669-680.
7. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature 2010; 464:224-231.
8. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464:217-223.
9. de Rocquigny H, Shvadchak V, Avilov S, Dong CZ, Dietrich U, Darlix JL, et al. Targeting the viral nucleocapsid protein in anti-HIV-1 therapy. Mini Rev Med Chem 2008; 8:24-35. (Pubitemid 351320927)
10. Goldschmidt V, Miller Jenkins LM, De Rocquigny H, Darlix JL, Mely Y. The nucleocapsid protein of HIV-1 as a promising therapeutic target for antiviral drugs. HIV Ther 2010; 4: 179.
11. Gorelick RJ, Nigida SM Jr, Bess JW Jr, Arthur LO, Henderson LE, Rein A. Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA. J Virol 1990; 64:3207-3211. (Pubitemid 20219523)
12. Rein A, Henderson LE, Levin JG. Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: significance for viral replication. Trends Biochem Sci 1998; 23:297-301. (Pubitemid 28461895)
13. Rice WG, Schaeffer CA, Harten B, Villinger F, South TL, Summers MF, et al. Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds. Nature 1993; 361:473-475. (Pubitemid 23050140)
14. Thomas JA, Gorelick RJ. Nucleocapsid protein function in early infection processes. Virus Res 2008; 134:39-63.
15. Turpin JA, Schito ML, Jenkins LM, Inman JK, Appella E. Topical microbicides: a promising approach for controlling the AIDS pandemic via retroviral zinc finger inhibitors. Adv Pharmacol 2008; 56:229-256.
16. Jenkins LMM, Byrd JC, Hara T, Srivastava P, Mazur S, Stahl SJ, et al. Studies on the inactivation of the HIV-1 nucleocapsid protein NCp7 with 2-mercaptobenzamide thioesters. J Med Chem 2005, 48:2847-2858. (Pubitemid 40548099)
17. Turpin JA, Song Y, Inman JK, Huang M, Wallqvist A, Maynard A, et al. Synthesis and biological properties of novel pyridinioalk-anoyl thiolesters (PATE) as anti-HIV-1 agents that target the viral nucleocapsid protein zinc fingers. J Med Chem 1999; 42:67-86. (Pubitemid 29056490)
18. Jenkins LM, Ott DE, Hayashi R, Coren LV, Wang D, Xu Q, et al. Small-molecule inactivation of HIV-1 NCp7 by repetitive in-tracellular acyl transfer. Nat Chem Biol 2010; 6:887-889.
19. Srivastava P, Schito M, Fattah RJ, Hara T, Hartman T, Buckheit RW Jr, et al. Optimization of unique, uncharged thioesters as inhibitors of HIV replication. Bioorg Med Chem 2004; 12:6437-6450. (Pubitemid 39535167)
20. Turpin JA, Terpening SJ, Schaeffer CA, Yu G, Glover CJ, Felsted RL, et al. Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles. J Virol 1996; 70:6180-6189. (Pubitemid 26266836)
21. Wallace GS, Cheng-Mayer C, Schito ML, Fletcher P, Miller Jenkins LM, Hayashi R, et al. Human immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection. J Virol 2009; 83:9175-9182.
22. Schito ML, Goel A, Song Y, Inman JK, Fattah RJ, Rice WG, et al. In vivo antiviral activity of novel human immunodeficiency virus type1nucleocapsidp7zincfinger inhibitorsinatransgenic murine model. AIDS Res Hum Retroviruses 2003; 19:91-101. (Pubitemid 36308046)
23. Schito ML, Soloff AC, Slovitz D, Trichel A, Inman JK, Appella E, et al. Preclinical evaluation of a zinc finger inhibitor targeting lentivirus nucleocapsid protein in SIV-infected monkeys. Curr HIV Res 2006; 4:379-386. (Pubitemid 44027725)
24. Liu J, Keele BF, Li H, Keating S, Norris PJ, Carville A, et al. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol 2010; 84:10406-10412.
25. Knapp LA, Lehmann E, Piekarczyk MS, Urvater JA, Watkins DI. A high frequency of Mamu-AM01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing. Tissue Antigens 1997; 50:657-661. (Pubitemid 28005842)
26. Huang Y, Krasnitz M, Rabadan R, Witten DM, Song Y, Levine AJ, et al. A recoding method to improve the humoral immune response to an HIV DNA vaccine. PLoS One 2008; 3:e3214.
27. Harouse JM, Gettie A, Eshetu T, Tan RC, Bohm R, Blanchard J, et al. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol 2001; 75:1990-1995. (Pubitemid 32110190)
28. Tien D, Schnaare RL, Kang F, Cohl G, McCormick TJ, Moench TR, et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 2005; 21:845-853. (Pubitemid 43150316)
29. Marx PA, Spira AI, Gettie A, Dailey PJ, Veazey RS, Lackner AA, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996; 2:1084-1089. (Pubitemid 26338626)
30. Stamatatos L, Werner A, Cheng-Mayer C. Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1. J Virol 1994; 68:4973-4979. (Pubitemid 24226563)
31. Letvin NL, Huang Y, Chakrabarti BK, Xu L, Seaman MS, Beaudry K, et al. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 2004; 78:7490-7497. (Pubitemid 38915894)
32. R central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006; 312:1530-1533. (Pubitemid 43865893)
33. Regoes RR, Longini IM, Feinberg MB, Staprans SI. Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges. PLoS Med 2005; 2:e249.
34. R T cells. Nature 2002; 417:95-98. (Pubitemid 34498823)
35. Zhang ZQ, Fu TM, Casimiro DR, Davies ME, Liang X, Schleif WA, et al. Mamu-AM01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J Virol 2002; 76:12845-12854. (Pubitemid 35386968)
36. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-1153. (Pubitemid 32378686)
37. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170. (Pubitemid 26001148)
38. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929. (Pubitemid 30177052)
39. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-1409. (Pubitemid 40563350)
40. Schito ML, Kennedy PE, Kowal RP, Berger EA, Sher A. A human immunodeficiency virus-transgenic mouse model for assessing interventions that block microbial-induced proviral expression. J Infect Dis 2001; 183:1592-1600. (Pubitemid 32466696)